On May 13, 2025 Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs (Press release, Invenra, MAY 13, 2025, View Source [SID1234652999]). Building on the success of Invenra’s B-Body bispecific platform, the T-Body platform expands the company’s capabilities to address complex therapeutic targets with enhanced developability.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential," said Roland Green, Ph.D., CEO and Chairman of Invenra. "By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we’re empowering partners to rapidly discover and advance a new class of multispecific therapeutics."
Designed for Versatility and Manufacturability
The T-Body platform features an IgG-like architecture with proprietary CH3 domain pairs that substitute for traditional CH1/CL domains in two Fab arms. This configuration improves chain pairing, reduces mispairing, and supports efficient expression and assembly in mammalian cells. The design also enables "Plug & Play" variable domain compatibility, allowing insertion of VH/VL pairs from diverse sources—including phage libraries, humanized mice, and AI-designed antibodies.
Invenra’s T-Body platform features include:
Proprietary CH3 Design: Improves heavy/light chain pairing and overall assembly.
Streamlined Purification: One-step purification with Protein A and anti-CH1 resin compatibility.
Robust Expression: High yields in multiple transient expression systems.
Flexible Targeting: Supports multivalent and/or multispecific formats with both kappa and lambda light chains.
Manufacturing-Ready: Compatible with standard IgG production processes for rapid scale-up.
Expanding the Future of Multispecific Antibodies
With the T-Body platform, Invenra continues its mission to accelerate next-generation multispecific antibody discovery in areas such as oncology, autoimmune disease, and immunotherapy. The platform’s modularity and developability profile position it for internal programs and strategic partnerships aimed at addressing complex biology through engineered multispecific formats.
"This platform is a natural extension of our antibody engineering leadership," Green added. "We’re excited to work with partners to move trispecific candidates from concept to clinic."
Invenra is highlighting the T-Body platform at the 21st Annual PEGS Boston May 12-16, with details available at its poster (A051), booth (612), and online at invenra.com.